INTERVIEW: Is An Early M&A Exit In Store For Clinical-Stage Axonics?
This article was originally published in Clinica
Executive Summary
Axonics Modulation Technologies may have barely initiated clinical trials of its implantable sacral neuromodulation (SNM) system for managing urinary and fecal dysfunction, but the company has already attracted attention from some of medtech’s big players seeking to buy into a segment of the neuromodulation market that may be worth more than $1bn a few years from now.